[CAS NO. 65373-29-7] MS21570
PRODUCTS SPECIFICATIONS [65373-29-7]
DESCRIPTION [65373-29-7]
Overview
| MDL | MFCD01018163 |
|---|---|
| Molecular Weight | 237.34 |
| Molecular Formula | C10H11N3S2 |
| SMILES | CNC1=NN=C(SCC2=CC=CC=C2)S1 |
Summary
MS21570 is a selective GPR171 antagonist, with an IC 50 of 220 nM.
IC50 & Target
IC50: 220 nM (GPR171) [1] .
In Vivo
MS21570 significantly attenuates this CNO-mediated increase in food intake. Interestingly, MS21570 causes a significant increase in center time compared to vehicle suggesting an effect on the anxiety-like behavior. Intra-BLA administration of MS21570 leads to an increase in open arm time on the elevated plus maze although there is no effect on locomotor activity during this test. Interestingly, when administered before and immediately following fear conditioning, MS21570 significantly attenuates freezing measured 24 hours later. Behavioral differences between systemic and intra-BLA administration of MS21570 could be due to the pharmacokinetic and pharmacodynamic properties of the drug. Further studies are needed to characterize the GPR171 antagonist [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 125 mg/mL ( 526.67 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 4.2134 mL | 21.0668 mL | 42.1336 mL |
| 5 mM | 0.8427 mL | 4.2134 mL | 8.4267 mL |
| 10 mM | 0.4213 mL | 2.1067 mL | 4.2134 mL |